Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Holdings Raised by Nilsine Partners LLC

Nilsine Partners LLC grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 64.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,249 shares of the biopharmaceutical company's stock after acquiring an additional 21,730 shares during the quarter. Nilsine Partners LLC's holdings in Catalyst Pharmaceuticals were worth $1,340,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth $27,000. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth $29,000. Farther Finance Advisors LLC grew its stake in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares during the last quarter. Sound Income Strategies LLC bought a new position in Catalyst Pharmaceuticals during the 1st quarter worth $64,000. Finally, GAMMA Investing LLC grew its stake in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 579 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $22.48 on Friday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.75 and a 1 year high of $26.58. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of 14.32, a PEG ratio of 0.92 and a beta of 0.72. The business has a fifty day moving average of $23.94 and a 200-day moving average of $22.90.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CPRX shares. Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens restated an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $32.83.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,000 shares of the company's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the sale, the insider now owns 68,873 shares in the company, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider now owns 41,081 shares of the company's stock, valued at approximately $1,085,360.02. This trade represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is currently owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.